To determine the potential utility of combining CSF1R inhibitors with currently approved therapies for CLL, we evaluated the sensitivity of patient samples to GW-2580 and ARRY-382 in combination with ibrutinib or idelalisib. Here, CSF1R is linked to B-cell chronic lymphocytic leukemia.